Nightstar Therapeutics plc (“
Nightstar”) is
pleased to announce that the High Court of Justice of England and
Wales today sanctioned the scheme of arrangement under Part 26 of
the Companies Act pursuant to which Tungsten Bidco Limited, a
newly-incorporated company and wholly-owned indirect subsidiary of
Biogen Inc., will acquire the entire issued and to be issued share
capital of Nightstar (the “
Acquisition”).
All Conditions to the Acquisition have now been
satisfied or waived other than delivery to the Registrar of
Companies of England and Wales of a copy of the Court Order, which
is expected to take place on 7 June 2019, at which point the Scheme
will become Effective.
Full details of the Acquisition are set out in
the combined circular and proxy statement dated 9 April 2019 (the
“Scheme Document”). Unless otherwise defined
herein, capitalised terms and expressions used in this announcement
shall have the meanings given to them in the Scheme Document.
Intention to delist Nightstar American
Depositary Shares (“ADSs”)
In connection with and conditional upon the
Scheme becoming Effective, Nightstar intends to request that the
Nasdaq Global Market (“Nasdaq”) file a
notification of removal from listing and registration on Form 25
with the U.S. Securities and Exchange Commission
(“SEC”) on 7 June 2019 to effect the delisting of
Nightstar from Nasdaq and the deregistration of Nightstar’s ADSs
under Section 12(b) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”).
The cancellation of listing of Nightstar’s ADSs
is expected to become fully effective on 17 June 2019. In addition,
Nightstar intends to file a certification on Form 15 with the SEC
requesting the termination of registration of its ADSs under
Section 12(g) of the Exchange Act and the suspension of
Nightstar’s reporting obligations under Sections 13 and 15(d) of
the Exchange Act with respect to its ADSs.
Enquiries: |
Nightstar |
|
Investor Information |
investors@nightstartx.com |
Media Enquiries |
media@nightstartx.com |
Information |
info@nightstartx.com |
Centerview Partners (Financial adviser to
Nightstar) |
Alan Hartman |
+1 212 380 2665 |
Andrew Rymer |
+1 212 429 2349 |
James Hartop |
+44 (0)20 7409 9730 |
Finsbury (PR adviser to
Nightstar) |
Kal Goldberg |
+1 646 805 2005 |
Chris Ryall |
+1 646 306 0747 |
Abigail Farr |
+1 646 805 2090 |
Important notices relating to financial
advisers
Centerview Partners UK LLP ("Centerview
Partners"), which is authorised and regulated by the FCA,
is acting exclusively for Nightstar and no one else in connection
with the matters referred to in this announcement. Centerview
Partners is not and will not be responsible to anyone other than
Nightstar for providing the protections afforded to its clients or
for providing advice in connection with the contents of this
announcement or any matter referred to in this announcement.
The City Code on Takeovers and
Mergers
The City Code on Takeovers and Mergers does not
apply to the Acquisition.
Overseas shareholders
The release, publication or distribution of this
announcement in jurisdictions other than the United Kingdom and the
United States may be restricted by law and therefore any persons
who are subject to the laws of any jurisdiction other than the
United Kingdom or the United States (including Restricted
Jurisdictions) should inform themselves about, and observe, any
applicable legal or regulatory requirements. Any failure to comply
with applicable legal or regulatory requirements of any
jurisdiction may constitute a violation of securities laws in that
jurisdiction. This announcement has been prepared for the purpose
of complying with English law and the information disclosed may not
be the same as that which would have been disclosed if this
announcement had been prepared in accordance with the laws of
jurisdictions outside England.
Copies of this announcement and any formal
documentation relating to the Acquisition are not being, and must
not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in or into or from any Restricted Jurisdiction
or any jurisdiction where to do so would constitute a violation of
the laws of such jurisdiction and persons receiving such documents
(including custodians, nominees and trustees) must not mail or
otherwise forward, distribute or send them in or into or from any
Restricted Jurisdiction. Doing so may render invalid any related
purported vote in respect of acceptance of the Acquisition.
If the Acquisition is implemented by way of an
Offer, the Offer may not (unless otherwise permitted by applicable
law and regulation) be made, directly or indirectly, in or into or
by use of the mails or any other means or instrumentality
(including, without limitation, facsimile, e-mail or other
electronic transmission, telex or telephone) of interstate or
foreign commerce of, or any facility of a national, state or other
securities exchange of any Restricted Jurisdiction and the
Acquisition will not be capable of acceptance by any such use,
means, instrumentality or facilities or from within any Restricted
Jurisdiction.
Further details in relation to Nightstar
Shareholders in overseas jurisdictions are contained in the Scheme
Document.
Notice to U.S. investors in
Nightstar
The Acquisition relates to the shares of a U.K.
company and is being made by means of a scheme of arrangement
provided for under Part 26 of the Companies Act 2006 and subject to
the proxy solicitation rules under the U.S. Exchange Act. The
Acquisition, implemented by way of a scheme of arrangement, is not
subject to the tender offer rules under the U.S. Exchange Act. If,
in the future, Bidder exercises its right to implement the
Acquisition by way of an Offer, subject to the terms of the
Implementation Agreement, the Acquisition will be made in
compliance with applicable U.S. laws and regulations.
It may be difficult for U.S. Nightstar
Shareholders and Nightstar ADS Holders to enforce their rights and
any claim arising out of the U.S. federal securities laws, because
Nightstar is located in a non-U.S. country, and some or all of its
officers and directors are residents of a non-U.S. country. U.S.
Nightstar Shareholders and Nightstar ADS Holders may not be able to
sue a non-U.S. company or its officers or directors in a non-U.S.
court for violations of the U.S. securities laws. Further, it may
be difficult to compel a non-U.S. company and its affiliates to
subject themselves to a U.S. court's judgment.
U.S. Nightstar Shareholders and Nightstar ADS
Holders are urged to consult with legal, tax and financial advisers
in connection with making a decision regarding the Acquisition.
Warning Concerning Forward-Looking
Statements
All statements included in this announcement,
other than statements or characterisations of historical fact, are
forward-looking statements within the meaning of the federal
securities laws, including Section 21E of the U.S. Exchange Act,
and other securities laws. Whenever Nightstar uses words such as
"believe", "expect", "anticipate", "intend", "plan", "estimate",
"will", "may", "predict", "could", "seek", "forecast" and negatives
or derivatives of these or similar expressions, they are making
forward-looking statements. Examples of such forward-looking
statements include, but are not limited to, references to the
anticipated benefits of the Acquisition and the expected time of
effectiveness of the Acquisition. These forward-looking statements
are based upon Nightstar's present intent, beliefs or expectations,
but forward-looking statements are not guaranteed to occur and may
not occur.
Nightstar Shareholders are cautioned that any
forward-looking statements are not guarantees of future performance
and may involve significant risks and uncertainties, and that
actual results may vary materially from those in the
forward-looking statements. Important risk factors that may cause
Nightstar's actual results to differ materially from their
forward-looking statements include, but are not limited to: (1) the
Acquisition is subject to the satisfaction or waiver of certain
conditions, which conditions may not be satisfied or waived; (2)
uncertainties as to the timing of the consummation of the
Acquisition and the ability of each party to consummate the
Acquisition; (3) the risk that the Acquisition disrupts the
parties' current operations or affects their ability to retain or
recruit key employees; (4) the possible diversion of management
time on Acquisition-related issues; (5) litigation relating to the
Acquisition; (6) unexpected costs, charges or expenses resulting
from the Acquisition; and (7) potential adverse reactions or
changes to business relationships resulting from the announcement
or completion of the Acquisition.
The information contained in Nightstar's filings
with SEC, including in Nightstar's Form 10-K, as amended by Form
10-K/A, for the year ended 31 December 2018, identifies other
important factors that could cause actual results to differ
materially from those stated in or implied by the forward-looking
statements in this announcement. Nightstar's filings with the SEC
are available on the SEC's website at www.sec.gov. You should not
place undue reliance upon forward-looking statements. Except as
required by law, Nightstar does not intend to update or change any
forward-looking statements as a result of new information, future
events or otherwise.
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2025 to Apr 2025
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2024 to Apr 2025